enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Hold” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus recommendation of “Hold” from the fourteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $12.6818.

Several equities research analysts have recently issued reports on ENGN shares. Wall Street Zen lowered enGene from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Citizens Jmp lowered shares of enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. UBS Group reduced their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Raymond James Financial downgraded shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 target price for the company. in a research report on Friday, May 8th. Finally, Guggenheim downgraded shares of enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th.

Hedge Funds Weigh In On enGene

Several institutional investors have recently bought and sold shares of ENGN. Privium Fund Management B.V. bought a new position in shares of enGene in the 4th quarter valued at approximately $3,179,000. Braidwell LP bought a new stake in enGene during the third quarter worth approximately $15,479,000. PFS Partners LLC grew its holdings in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after purchasing an additional 2,000 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in enGene during the third quarter valued at approximately $76,000. Finally, Monashee Investment Management LLC raised its position in shares of enGene by 8.5% in the first quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after purchasing an additional 25,000 shares during the period. 64.16% of the stock is currently owned by institutional investors.

enGene Trading Up 7.5%

Shares of NASDAQ:ENGN opened at $1.73 on Friday. The firm has a fifty day moving average of $6.10 and a two-hundred day moving average of $7.85. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The firm has a market capitalization of $115.89 million, a P/E ratio of -0.77 and a beta of -0.02.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. On average, equities analysts expect that enGene will post -2.06 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.